stella
beta
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years — Stella
Recruiting
Back to HPV Infections trials
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations
(1 site)
China
Huakun Lv, Hangzhou
View full record on ClinicalTrials.gov